CN110114080A - 一种预防和治疗皮肤纤维化的方法 - Google Patents

一种预防和治疗皮肤纤维化的方法 Download PDF

Info

Publication number
CN110114080A
CN110114080A CN201780078123.9A CN201780078123A CN110114080A CN 110114080 A CN110114080 A CN 110114080A CN 201780078123 A CN201780078123 A CN 201780078123A CN 110114080 A CN110114080 A CN 110114080A
Authority
CN
China
Prior art keywords
plasminogen
drug
subject
skin
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078123.9A
Other languages
English (en)
Chinese (zh)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tailunji International Co ltd
Original Assignee
Tailunji International Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tailunji International Co ltd filed Critical Tailunji International Co ltd
Publication of CN110114080A publication Critical patent/CN110114080A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780078123.9A 2016-12-15 2017-06-19 一种预防和治疗皮肤纤维化的方法 Pending CN110114080A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016110174 2016-12-15
CNPCT/CN2016/110174 2016-12-15
PCT/CN2017/089054 WO2018107694A1 (zh) 2016-12-15 2017-06-19 一种预防和治疗皮肤纤维化的方法

Publications (1)

Publication Number Publication Date
CN110114080A true CN110114080A (zh) 2019-08-09

Family

ID=62557850

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780078123.9A Pending CN110114080A (zh) 2016-12-15 2017-06-19 一种预防和治疗皮肤纤维化的方法
CN201780078132.8A Pending CN110121358A (zh) 2016-12-15 2017-06-19 一种预防和治疗肺纤维化的方法
CN201780078169.0A Pending CN110191718A (zh) 2016-12-15 2017-06-19 一种预防和治疗组织器官纤维化的方法
CN201780078166.7A Pending CN110139668A (zh) 2016-12-15 2017-06-19 一种预防和治疗肝纤维化的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201780078132.8A Pending CN110121358A (zh) 2016-12-15 2017-06-19 一种预防和治疗肺纤维化的方法
CN201780078169.0A Pending CN110191718A (zh) 2016-12-15 2017-06-19 一种预防和治疗组织器官纤维化的方法
CN201780078166.7A Pending CN110139668A (zh) 2016-12-15 2017-06-19 一种预防和治疗肝纤维化的方法

Country Status (7)

Country Link
US (4) US20190314466A1 (enExample)
EP (4) EP3556382A4 (enExample)
JP (4) JP7213553B2 (enExample)
CN (4) CN110114080A (enExample)
CA (4) CA3046666A1 (enExample)
TW (6) TWI752044B (enExample)
WO (5) WO2018107694A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190314466A1 (en) 2016-12-15 2019-10-17 Talengen International Limited Method for preventing and treating skin fibrosis
TWI714862B (zh) 2017-06-19 2021-01-01 大陸商深圳瑞健生命科學硏究院有限公司 一種調控glp-1/glp-1r的方法和藥物
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CA3167593A1 (en) * 2020-02-11 2021-08-19 Jinan Li Method and drug for treating viral pneumonia
CN114984032B (zh) * 2022-06-27 2023-07-07 四川大学 Dna四面体框架核酸-绿原酸复合物及其在制备治疗肝纤维化的药物中的用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
WO2000010506A2 (en) * 1998-08-20 2000-03-02 University Of Vermont And State Agriculture College Angiogenesis inhibitors and uses thereof
US20040043026A1 (en) * 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20090227515A1 (en) * 2008-03-05 2009-09-10 Board Of Regents, The University Of Texas System Peptide Inhibition of Lung Epithelial Apoptosis and Pulmonary Fibrosis
WO2011139973A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Methods of inhibiting fibrosis using anti-pai-1 antibodies
CN105705520A (zh) * 2013-08-13 2016-06-22 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
HU224827B1 (hu) * 1996-05-03 2006-02-28 Abbott Lab Új antiangiogén peptidek, azokat kódoló polinukleotidok, és eljárások angiogenezis gátlására
WO1999000420A1 (en) 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US20030054988A1 (en) 2000-11-02 2003-03-20 Weidong-Richard Ji Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
MXPA00011713A (es) 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050124036A1 (en) 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
AU2003210137A1 (en) * 2002-02-06 2003-09-02 N-Zyme Biotec Gmbh Method for producing recombinant proteins in micro-organisms
JP2006514640A (ja) 2002-12-10 2006-05-11 ワイス プラスミノゲンアクティベータインヒビターのインヒビターとしての置換３−アルキル及び３−アリールアルキル１ｈ−イル酢酸誘導体
US7186749B2 (en) 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
MX2009002226A (es) 2006-08-28 2009-09-07 Omnio Healer Ab Candidatos contra infeccion.
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
WO2009073471A1 (en) 2007-11-29 2009-06-11 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
AU2010270146B9 (en) 2009-07-10 2015-04-02 Thrombogenics Nv Variants of plasminogen and plasmin
CN101628113B (zh) * 2009-08-18 2012-01-04 南京农业大学 蚯蚓纤溶酶抗肝纤维化的应用
NZ600160A (en) 2009-11-07 2014-05-30 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
CN103384722B (zh) 2011-01-05 2016-11-16 斯路姆基因公司 纤溶酶原和纤溶酶变体
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
US9655973B2 (en) 2012-03-09 2017-05-23 Vascular Biosciences Orally active, cell-penetrating homing peptide and methods of using same
KR101467109B1 (ko) 2013-07-10 2014-12-01 영남대학교 산학협력단 Ｂｉｘ02189 화합물을 유효성분으로 포함하는 폐섬유증 예방 또는 치료용 조성물
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
US20160199466A1 (en) * 2013-08-20 2016-07-14 Trustees Of Dartmouth College Methods For Treating Tissue Fibrosis
PT3109320T (pt) 2014-02-21 2019-06-06 Astellas Pharma Inc Novo anticorpo anti-pai-1 humano
KR102692851B1 (ko) 2014-12-19 2024-08-06 프로메틱 바이오 테라퓨틱스 인코포레이티드 플라스미노겐을 포함하는 약학 조성물 및 이의 용도
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
CA3008694C (en) 2015-12-18 2022-11-29 Talengen International Limited Use of plasminogen for preventing or treating diabetic nerve injury and related disorders thereof
CA3008466C (en) 2015-12-18 2023-06-20 Talengen International Limited Method for preventing or treating radiation and chemical damage
CN106890324A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
CN106890320A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
DK3395359T5 (da) 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose
CN106890318A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病性心脏病的新方法
WO2017101871A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
TWI677348B (zh) * 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
US20190328850A1 (en) * 2016-12-15 2019-10-31 Talengen International Limited Method for preventing and treating lipid metabolism disorders and related diseases thereof
US20190314466A1 (en) 2016-12-15 2019-10-17 Talengen International Limited Method for preventing and treating skin fibrosis
JP7182793B2 (ja) * 2016-12-15 2022-12-05 タレンゲン インターナショナル リミテッド 病理学的腎組織損傷を予防及び治療するための方法
EP3556390B1 (en) 2016-12-15 2024-04-03 Talengen International Limited Plasminogen for use in treating diabetes
TWI714862B (zh) * 2017-06-19 2021-01-01 大陸商深圳瑞健生命科學硏究院有限公司 一種調控glp-1/glp-1r的方法和藥物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
WO2000010506A2 (en) * 1998-08-20 2000-03-02 University Of Vermont And State Agriculture College Angiogenesis inhibitors and uses thereof
US20040043026A1 (en) * 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20090227515A1 (en) * 2008-03-05 2009-09-10 Board Of Regents, The University Of Texas System Peptide Inhibition of Lung Epithelial Apoptosis and Pulmonary Fibrosis
WO2011139973A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Methods of inhibiting fibrosis using anti-pai-1 antibodies
CN105705520A (zh) * 2013-08-13 2016-06-22 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GHOSH,A. K.等: "PAI-1 in Tissue Fibrosis", 《JOURNAL OF CELLULAR PHYSIOLOGY》 *
GIORGIO-MILLER,A.等: "Fibrin-Induced Skin Fibrosis in Mice Deficient in Tissue Plasminogen Activator", 《AMERICAN JOURNAL OF PATHOLOGY》 *

Also Published As

Publication number Publication date
TWI670075B (zh) 2019-09-01
JP7313058B2 (ja) 2023-07-24
TW201822796A (zh) 2018-07-01
TW202123955A (zh) 2021-07-01
EP3556382A4 (en) 2020-12-09
EP3556380A1 (en) 2019-10-23
JP2020511413A (ja) 2020-04-16
TWI734798B (zh) 2021-08-01
JP2020502132A (ja) 2020-01-23
EP3556382A1 (en) 2019-10-23
JP7213552B2 (ja) 2023-01-27
EP3556395A1 (en) 2019-10-23
EP3556380A4 (en) 2020-05-13
WO2018107698A1 (zh) 2018-06-21
TW201822790A (zh) 2018-07-01
CA3046671C (en) 2023-08-08
CN110121358A (zh) 2019-08-13
WO2018107694A1 (zh) 2018-06-21
CN110191718A (zh) 2019-08-30
WO2018107696A1 (zh) 2018-06-21
TW201822789A (zh) 2018-07-01
CA3046671A1 (en) 2018-06-21
US11071772B2 (en) 2021-07-27
CA3046666A1 (en) 2018-06-21
WO2018107693A1 (zh) 2018-06-21
CN110139668A (zh) 2019-08-16
US11219669B2 (en) 2022-01-11
JP2020502133A (ja) 2020-01-23
EP3556395A4 (en) 2020-07-22
JP7213553B2 (ja) 2023-01-27
TWI752044B (zh) 2022-01-11
WO2018107697A1 (zh) 2018-06-21
CA3046669A1 (en) 2018-06-21
US20190314468A1 (en) 2019-10-17
EP3556389A1 (en) 2019-10-23
US20190314466A1 (en) 2019-10-17
US20190314467A1 (en) 2019-10-17
US20190365872A1 (en) 2019-12-05
JP2020512288A (ja) 2020-04-23
TW201822783A (zh) 2018-07-01
CA3047174A1 (en) 2018-06-21
US11154595B2 (en) 2021-10-26
TW201822795A (zh) 2018-07-01
EP3556389A4 (en) 2020-07-15
TWI657823B (zh) 2019-05-01

Similar Documents

Publication Publication Date Title
CN110114080A (zh) 一种预防和治疗皮肤纤维化的方法
Dhillon et al. Improvising PRP for use in osteoarthritis knee-upcoming trends and futuristic view
Murakami et al. Pharmacotherapy for keloids and hypertrophic scars
US20180369136A1 (en) Devices and methods for transdermal treatment of basal cell carcinoma
JP2014503587A (ja) 界面活性剤組成物
JP2014503586A (ja) 油組成物
US20210275442A1 (en) Topical skin formulations and wound care products with integrated cbd delivery mechanisms for skin rejuvenation
Han et al. Microneedle-based approaches for skin disease treatment
TW201603818A (zh) 組成物及方法
KR20140012651A (ko) 파라벤 조성물
Bart et al. Salicylic acid in karaya gum patch as a treatment for verruca vulgaris
WO2019029154A1 (zh) 一种经皮吸收组合物及其在制备经皮吸收制剂中的用途
US20040087544A1 (en) Pharmaceutical compositions of topic use, applied in treatment of skin and/or mucous injuries use of compositions in treatment of skin and/or mucous injuries and use of compounds in treatment of skin and/or mucous injuries
Papp et al. The safety and tolerability of topically delivered kynurenic acid in humans. A phase 1 randomized double-blind clinical trial
Kaur et al. Formulation strategies and therapeutic applications of shikonin and related derivatives
Singhal et al. Fractional laser ablation for the cutaneous delivery of triamcinolone acetonide from cryomilled polymeric microparticles: creating intraepidermal drug depots
Hema et al. A review on recent advances and challenges of microneedle technology for enhanced topical treatment of skin disorders
Mishra et al. Nanocarrier and herbal based transdermal patch: an advantage over other drug delivery systems
CN110366427A (zh) 一种预防和治疗病理性肾组织损伤的方法
US20190000936A1 (en) Prophylactic normalization of cutaneous wound repair
JP2024055895A (ja) 基底細胞がんおよび神経膠芽腫を治療する方法
EP3173066A1 (en) Plaster comprising antiedematous substances for the treatment of bruising and injury
EP2712613A1 (en) Vitamin K1 and uses thereof
RU2423971C1 (ru) Способ ускорения заживления кожных повреждений, вызванных денервацией и нарушением кровоснабжения
WO2019108903A1 (en) Methods of treating skin lesions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination